HIV-1 gag-pol

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Capsid protein HIV-1 gag-pol: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.
  • TCR Cell Products

Loading...
  • Cell Type:
  • Target:
  • HLA:
  • Epitope:
CAT Product Name Cell Type Target HLA Epitope Inquiry & Datasheet
TCRJ-CQ130 Anti-HIV-1 gag-pol (KRWIILGLNK) T Cell Receptor (TCRJ-CQ130), Jurkat Cell Line T lymphocyte HIV-1 gag-pol HLA-B27 KRWIILGLNK   Add to Cart   Datasheet
XS-0623-ZP153 Anti-HIV-1 gag-pol TCR-NK Cells TCR-NK HIV-1 gag-pol   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.